Small RNA sequencing reveals a comprehensive miRNA signature ofBRCA1-associated high-grade serous ovarian cancer

miR-145, targeting high-mobility group A2, is a powerful predictor of patient outcome in ovarian carcinoma

(2015) Tae Hoen Kim et al.   CANCER LETTERS

Uncovering the clinical utility of miR-143, miR-145 and miR-224 for predicting the survival of bladder cancer patients following treatment

(2015) Margaritis Avgeris et al.   CARCINOGENESIS

Whole–genome characterization of chemoresistant ovarian cancer

(2015) Ann-Marie Patch et al.   NATURE

miR-145 inhibits tumor growth and metastasis by targeting metadherin in high-grade serous ovarian carcinoma

(2015) Ruifen Dong et al.   Oncotarget

Risk reducing salpingo-oophorectomy for BRCA mutation carriers: Twenty years later

(2014) C. Bethan Powell   GYNECOLOGIC ONCOLOGY

An evaluation and replication of miRNAs with disease stage and colorectal cancer-specific mortality

(2014) Martha L. Slattery et al.   INTERNATIONAL JOURNAL OF CANCER

MiR-145 acts as a metastasis suppressor by targeting metadherin in lung cancer

(2014) Mingzhi Wang et al.   MEDICAL ONCOLOGY

Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas

(2013) Kathryn P. Pennington et al.   CLINICAL CANCER RESEARCH

Meta-analysis of microRNA-183 family expression in human cancer studies comparing cancer tissues with noncancerous tissues

(2013) Qing-He Zhang et al.   GENE

Outcome of unexpected adnexal neoplasia discovered during risk reduction salpingo-oophorectomy in women with germ-line BRCA1 or BRCA2 mutations

(2013) James R. Conner et al.   GYNECOLOGIC ONCOLOGY

Plasma miRNAs as Diagnostic and Prognostic Biomarkers for Ovarian Cancer

(2013) Hong Zheng et al.   PLoS One

BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group

(2012) Kathryn Alsop et al.   JOURNAL OF CLINICAL ONCOLOGY

MiR-182 overexpression in tumourigenesis of high-grade serous ovarian carcinoma

(2012) Zhaojian Liu et al.   JOURNAL OF PATHOLOGY

Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients

(2011) P. M. L. H. Vencken et al.   ANNALS OF ONCOLOGY

Integrated genomic analyses of ovarian carcinoma

(2011) D. Bell et al.   NATURE

miRDeep2 accurately identifies known and hundreds of novel microRNA genes in seven animal clades

(2011) Marc R. Friedländer et al.   NUCLEIC ACIDS RESEARCH

Are All Pelvic (Nonuterine) Serous Carcinomas of Tubal Origin?

(2010) Christopher G. Przybycin et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary

(2010) Ahmed Ashour Ahmed et al.   JOURNAL OF PATHOLOGY

Widespread Estrogen-Dependent Repression of microRNAs Involved in Breast Tumor Cell Growth

(2009) G. Maillot et al.   CANCER RESEARCH

Estradiol downregulates miR-21 expression and increases miR-21 target gene expression in MCF-7 breast cancer cells

(2009) Nalinie S. Wickramasinghe et al.   NUCLEIC ACIDS RESEARCH

MicroRNA Profiling of BRCA1/2 Mutation-Carrying and Non-Mutation-Carrying High-Grade Serous Carcinomas of Ovary

(2009) Cheng-Han Lee et al.   PLoS One